JP2017530182A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2017530182A5 JP2017530182A5 JP2017518943A JP2017518943A JP2017530182A5 JP 2017530182 A5 JP2017530182 A5 JP 2017530182A5 JP 2017518943 A JP2017518943 A JP 2017518943A JP 2017518943 A JP2017518943 A JP 2017518943A JP 2017530182 A5 JP2017530182 A5 JP 2017530182A5
- Authority
- JP
- Japan
- Prior art keywords
- pharmaceutical composition
- composition according
- diabetes
- alkenyl
- alkyl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 150000001875 compounds Chemical class 0.000 claims description 30
- 239000008194 pharmaceutical composition Substances 0.000 claims description 24
- 150000003839 salts Chemical class 0.000 claims description 19
- 206010012601 diabetes mellitus Diseases 0.000 claims description 14
- 239000008280 blood Substances 0.000 claims description 9
- 210000004369 blood Anatomy 0.000 claims description 9
- 239000003814 drug Substances 0.000 claims description 9
- 208000001072 type 2 diabetes mellitus Diseases 0.000 claims description 9
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 claims description 8
- 239000008103 glucose Substances 0.000 claims description 8
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 claims description 8
- 229940124597 therapeutic agent Drugs 0.000 claims description 8
- 206010022489 Insulin Resistance Diseases 0.000 claims description 7
- 206010067584 Type 1 diabetes mellitus Diseases 0.000 claims description 6
- 230000002265 prevention Effects 0.000 claims description 5
- 208000031226 Hyperlipidaemia Diseases 0.000 claims description 4
- 102000004877 Insulin Human genes 0.000 claims description 4
- 108090001061 Insulin Proteins 0.000 claims description 4
- XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 claims description 4
- 229940125396 insulin Drugs 0.000 claims description 4
- UFTFJSFQGQCHQW-UHFFFAOYSA-N triformin Chemical compound O=COCC(OC=O)COC=O UFTFJSFQGQCHQW-UHFFFAOYSA-N 0.000 claims description 4
- ZOBPZXTWZATXDG-UHFFFAOYSA-N 1,3-thiazolidine-2,4-dione Chemical compound O=C1CSC(=O)N1 ZOBPZXTWZATXDG-UHFFFAOYSA-N 0.000 claims description 3
- 208000032928 Dyslipidaemia Diseases 0.000 claims description 3
- 208000002705 Glucose Intolerance Diseases 0.000 claims description 3
- 206010018429 Glucose tolerance impaired Diseases 0.000 claims description 3
- 206010060378 Hyperinsulinaemia Diseases 0.000 claims description 3
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 claims description 3
- 208000017170 Lipid metabolism disease Diseases 0.000 claims description 3
- 208000001145 Metabolic Syndrome Diseases 0.000 claims description 3
- 229940123464 Thiazolidinedione Drugs 0.000 claims description 3
- 201000000690 abdominal obesity-metabolic syndrome Diseases 0.000 claims description 3
- 230000007423 decrease Effects 0.000 claims description 3
- 201000001421 hyperglycemia Diseases 0.000 claims description 3
- 230000003451 hyperinsulinaemic effect Effects 0.000 claims description 3
- 201000008980 hyperinsulinism Diseases 0.000 claims description 3
- XZWYZXLIPXDOLR-UHFFFAOYSA-N metformin Chemical group CN(C)C(=N)NC(N)=N XZWYZXLIPXDOLR-UHFFFAOYSA-N 0.000 claims description 3
- 229960003105 metformin Drugs 0.000 claims description 3
- 229910052708 sodium Inorganic materials 0.000 claims description 3
- 239000011734 sodium Substances 0.000 claims description 3
- QGZKDVFQNNGYKY-UHFFFAOYSA-O Ammonium Chemical compound [NH4+] QGZKDVFQNNGYKY-UHFFFAOYSA-O 0.000 claims description 2
- 201000001320 Atherosclerosis Diseases 0.000 claims description 2
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 claims description 2
- RYGMFSIKBFXOCR-UHFFFAOYSA-N Copper Chemical compound [Cu] RYGMFSIKBFXOCR-UHFFFAOYSA-N 0.000 claims description 2
- 208000032131 Diabetic Neuropathies Diseases 0.000 claims description 2
- 206010012689 Diabetic retinopathy Diseases 0.000 claims description 2
- 208000035150 Hypercholesterolemia Diseases 0.000 claims description 2
- WHXSMMKQMYFTQS-UHFFFAOYSA-N Lithium Chemical compound [Li] WHXSMMKQMYFTQS-UHFFFAOYSA-N 0.000 claims description 2
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 claims description 2
- 208000008589 Obesity Diseases 0.000 claims description 2
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 claims description 2
- 201000001880 Sexual dysfunction Diseases 0.000 claims description 2
- HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 claims description 2
- 239000011575 calcium Substances 0.000 claims description 2
- 229910052791 calcium Inorganic materials 0.000 claims description 2
- 229910052802 copper Inorganic materials 0.000 claims description 2
- 239000010949 copper Substances 0.000 claims description 2
- 208000004104 gestational diabetes Diseases 0.000 claims description 2
- 208000020346 hyperlipoproteinemia Diseases 0.000 claims description 2
- 208000006575 hypertriglyceridemia Diseases 0.000 claims description 2
- 229910052742 iron Inorganic materials 0.000 claims description 2
- 229910052744 lithium Inorganic materials 0.000 claims description 2
- 239000011777 magnesium Substances 0.000 claims description 2
- 229910052749 magnesium Inorganic materials 0.000 claims description 2
- WPBNNNQJVZRUHP-UHFFFAOYSA-L manganese(2+);methyl n-[[2-(methoxycarbonylcarbamothioylamino)phenyl]carbamothioyl]carbamate;n-[2-(sulfidocarbothioylamino)ethyl]carbamodithioate Chemical compound [Mn+2].[S-]C(=S)NCCNC([S-])=S.COC(=O)NC(=S)NC1=CC=CC=C1NC(=S)NC(=O)OC WPBNNNQJVZRUHP-UHFFFAOYSA-L 0.000 claims description 2
- 229910052751 metal Inorganic materials 0.000 claims description 2
- 239000002184 metal Substances 0.000 claims description 2
- 235000020824 obesity Nutrition 0.000 claims description 2
- 229910052700 potassium Inorganic materials 0.000 claims description 2
- 239000011591 potassium Substances 0.000 claims description 2
- 231100000872 sexual dysfunction Toxicity 0.000 claims description 2
- 239000011701 zinc Substances 0.000 claims description 2
- 229910052725 zinc Inorganic materials 0.000 claims description 2
- 235000018936 Vitellaria paradoxa Nutrition 0.000 claims 1
- 230000033228 biological regulation Effects 0.000 claims 1
- 208000024891 symptom Diseases 0.000 claims 1
- 238000000034 method Methods 0.000 description 28
- 125000003342 alkenyl group Chemical group 0.000 description 12
- 125000000217 alkyl group Chemical group 0.000 description 12
- 230000003247 decreasing effect Effects 0.000 description 2
- 230000003914 insulin secretion Effects 0.000 description 2
- 239000000203 mixture Substances 0.000 description 2
- 206010070901 Diabetic dyslipidaemia Diseases 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 230000004203 pancreatic function Effects 0.000 description 1
- 230000008929 regeneration Effects 0.000 description 1
- 238000011069 regeneration method Methods 0.000 description 1
- 208000011580 syndromic disease Diseases 0.000 description 1
- 150000003626 triacylglycerols Chemical class 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201462062526P | 2014-10-10 | 2014-10-10 | |
| US62/062,526 | 2014-10-10 | ||
| PCT/CA2015/000531 WO2016054726A1 (en) | 2014-10-10 | 2015-10-08 | Substituted aromatic compounds and pharmaceutical compositions for the prevention and treatment of diabetes |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2017530182A JP2017530182A (ja) | 2017-10-12 |
| JP2017530182A5 true JP2017530182A5 (enExample) | 2018-11-22 |
| JP6676629B2 JP6676629B2 (ja) | 2020-04-08 |
Family
ID=55652427
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017518943A Expired - Fee Related JP6676629B2 (ja) | 2014-10-10 | 2015-10-08 | 糖尿病の予防及び治療用の置換芳香族化合物及び医薬組成物 |
Country Status (21)
| Country | Link |
|---|---|
| US (1) | US10105331B2 (enExample) |
| EP (1) | EP3203998B1 (enExample) |
| JP (1) | JP6676629B2 (enExample) |
| KR (1) | KR20170066614A (enExample) |
| CN (1) | CN106999458B (enExample) |
| AR (1) | AR102248A1 (enExample) |
| AU (1) | AU2015330643B2 (enExample) |
| BR (1) | BR112017007420A2 (enExample) |
| CA (1) | CA2963276A1 (enExample) |
| DK (1) | DK3203998T3 (enExample) |
| ES (1) | ES2875336T3 (enExample) |
| IL (1) | IL251392B (enExample) |
| MX (1) | MX376872B (enExample) |
| PH (1) | PH12017500662B1 (enExample) |
| PL (1) | PL3203998T3 (enExample) |
| PT (1) | PT3203998T (enExample) |
| RU (1) | RU2723486C2 (enExample) |
| SG (1) | SG11201702812PA (enExample) |
| TW (1) | TWI699201B (enExample) |
| UY (1) | UY36354A (enExample) |
| WO (1) | WO2016054726A1 (enExample) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SG11201702812PA (en) * | 2014-10-10 | 2017-05-30 | Prometic Pharma Smt Ltd | Substituted aromatic compounds and pharmaceutical compositions for the prevention and treatment of diabetes |
| US10391073B2 (en) * | 2014-11-12 | 2019-08-27 | Prometic Pharma Smt Limited | Substituted aromatic compounds and pharmaceutical compositions for tissue self-repair and regeneration |
| CA3112073A1 (en) | 2018-10-11 | 2020-04-16 | Basf As | Aromatic compounds and pharmaceutical uses thereof |
| US20240043372A1 (en) * | 2020-10-06 | 2024-02-08 | Pharmaceutique Ingenew Inc. | Substituted aromatic compounds and pharmaceutical compositions thereof |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5635532A (en) * | 1991-10-21 | 1997-06-03 | The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services | Compositions and methods for therapy and prevention of pathologies including cancer, AIDS and anemia |
| RU2005128501A (ru) * | 2003-02-13 | 2006-04-27 | Веллстат Терапьютикс Корпорейшн (Us) | Соединение для лечения метаболических расстройств |
| CA2580370A1 (en) * | 2004-09-15 | 2006-03-23 | Gokhan S. Hotamisligil | Reducing er stress in the treatment of obesity and diabetes |
| AT509045B1 (de) * | 2010-01-29 | 2011-06-15 | Planta Naturstoffe Vertriebsges M B H | Verbindungen zur behandlung von asthma bronchiale |
| JP2012072136A (ja) * | 2010-09-03 | 2012-04-12 | Erina Co Inc | 細胞内代謝促進用組成物、その組成物を含有する糖代謝又は脂質代謝疾患の予防及び／又は治療用医薬製剤、機能性食品及び健康食品 |
| CA2816094A1 (en) * | 2010-10-27 | 2012-07-26 | Prometic Biosciences Inc. | Compounds and pharmaceutical compositions for uses in diabetes |
| TWI689490B (zh) * | 2013-03-15 | 2020-04-01 | 英商邊緣生物科技有限公司 | 用於治療纖維化之經取代之芳族化合物及相關方法 |
| SG11201702812PA (en) * | 2014-10-10 | 2017-05-30 | Prometic Pharma Smt Ltd | Substituted aromatic compounds and pharmaceutical compositions for the prevention and treatment of diabetes |
-
2015
- 2015-10-08 SG SG11201702812PA patent/SG11201702812PA/en unknown
- 2015-10-08 CA CA2963276A patent/CA2963276A1/en not_active Abandoned
- 2015-10-08 MX MX2017004738A patent/MX376872B/es active IP Right Grant
- 2015-10-08 BR BR112017007420-6A patent/BR112017007420A2/pt not_active Application Discontinuation
- 2015-10-08 EP EP15849445.0A patent/EP3203998B1/en active Active
- 2015-10-08 CN CN201580066107.9A patent/CN106999458B/zh not_active Expired - Fee Related
- 2015-10-08 PL PL15849445T patent/PL3203998T3/pl unknown
- 2015-10-08 US US15/515,048 patent/US10105331B2/en active Active
- 2015-10-08 ES ES15849445T patent/ES2875336T3/es active Active
- 2015-10-08 PH PH1/2017/500662A patent/PH12017500662B1/en unknown
- 2015-10-08 JP JP2017518943A patent/JP6676629B2/ja not_active Expired - Fee Related
- 2015-10-08 DK DK15849445.0T patent/DK3203998T3/da active
- 2015-10-08 WO PCT/CA2015/000531 patent/WO2016054726A1/en not_active Ceased
- 2015-10-08 PT PT158494450T patent/PT3203998T/pt unknown
- 2015-10-08 RU RU2017116106A patent/RU2723486C2/ru active
- 2015-10-08 KR KR1020177012551A patent/KR20170066614A/ko not_active Ceased
- 2015-10-08 AU AU2015330643A patent/AU2015330643B2/en not_active Ceased
- 2015-10-12 TW TW104133395A patent/TWI699201B/zh not_active IP Right Cessation
- 2015-10-13 UY UY0001036354A patent/UY36354A/es not_active Application Discontinuation
- 2015-10-13 AR ARP150103296A patent/AR102248A1/es unknown
-
2017
- 2017-03-26 IL IL251392A patent/IL251392B/en active IP Right Grant
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2010514829A5 (enExample) | ||
| JP2018518537A5 (enExample) | ||
| JP2010514831A5 (enExample) | ||
| JP2011051993A5 (enExample) | ||
| JP2011527332A5 (enExample) | ||
| JP2010535252A5 (enExample) | ||
| TWI598098B (zh) | 脂質異常症治療劑 | |
| JP2010077141A5 (enExample) | ||
| JP2016528301A5 (enExample) | ||
| NZ586751A (en) | Use of CDDO methyl ester (methyl 2-cyano-3,12-dioxoleana-1,9(11)-dien-28-oate) for the treatment of renal diseases and for improving kigney function | |
| JP2013525444A5 (enExample) | ||
| JP2008007519A5 (enExample) | ||
| JP2017530182A5 (enExample) | ||
| JP2009504748A5 (enExample) | ||
| JP2009533356A5 (enExample) | ||
| JP2016534063A5 (enExample) | ||
| JP2018538273A5 (enExample) | ||
| JP2011527333A5 (enExample) | ||
| JP2012531402A5 (enExample) | ||
| JP2014505107A5 (enExample) | ||
| JP2019516739A5 (enExample) | ||
| JP2016537338A5 (enExample) | ||
| JP2019520344A5 (enExample) | ||
| JP2017105859A5 (enExample) | ||
| JP2011046708A5 (enExample) |